Jeffrey McCullough - Transfusion Medicine

58 58. Eder AF, Dy BA, Kennedy JM, et al. The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006. Transfusion 2008; 48:1809–1819.

59 59. Eder AF, Hillyer CD, Dy BA, et al. Adverse reactions to allogeneic whole blood donation by 16‐ and 17‐year olds. JAMA 2008; 299:2279–2286.

60 60. Newman BH, Newman DT, Ahmad R, Roth AJ. The effect of whole‐blood donor adverse events on blood donor return rates. Transfusion 2006; 46:1374–1379.

61 61. Popovsky MA. Vasovagal donor reactions: an important issue with implications for the blood supply. Transfusion 2002; 42:1534–1536.

62 62. Newman BH. Management of young blood donors. Transfus Med Hemother 2014; 41(4):284–295.

63 63. Wiltbank TB, Giordano GF, Kamel H, et al. Faint and prefaint reactions in whole‐blood donors: an analysis of predonation measurements and their predictive value. Transfusion 2008; 48:1799–1808.

64 64. Frances CR, Menitove JE. Mitigating adverse reactions in youthful donors. Transfusion 2008; 48:1774–1776.

65 65. Ando S, Kawamura N, Matsumoto M, et al. Simple standing test predicts and water ingestion prevents vasovagal reaction in the high‐risk blood donors. Transfusion 2009; 49:1630–1636.

66 66. Frances CR, Rader A, Carison B. Donors who react may not come back: analysis of repeat donation as a function of phlebotomist ratings of vasovagal reactions. Transfus Apher Sci 2005; 33:99–106.

67 67. France CR, France JL, Carlson BW, et al. Fear of blood draws, vasovagal reactions, and retention among high school donors. Transfusion 2014; 54(3):918–924.

68 68. Rigas A, Pedersen O, Rostgaard K, et al. Frequent blood donation and offspring scholastic attainment—an assessment of long‐term consequences of pre‐natal iron deficiency. Transfusion 2019; 59:1717–1722.

69 69. Spencer B, Bialkowski W, Creel D, et al. Elevated risk for iron depletion in high school age blood donors. Transfusion 2019; 59:1706–1716.

70 70. Krumholz A, Ness PM, Hauser WA, et al. Adverse reactions in blood donors with a history of seizures or epilepsy. Transfusion 1995; 35:470–474.

71 71. Newman BH, Waxman DA. Blood donation‐related neurologic needle injury: evaluation of 2 years’ worth of data from a large blood center. Transfusion 1996; 36:213–215.

72 72. Berry PR, Wallis WE. Venipuncture nerve injuries. Lancet 1977; 1:1236–1237.

73 73. Horowitz SH. Venipuncture‐induced causalgia: anatomic relations of upper extremity superficial veins and nerves, and clinical considerations. Transfusion 2000; 40:1036–1040.

74 74. Newman B. Arm complications after manual whole blood donation and their impact. Transf Med Rev 2013; 27(2):65–73.

75 75. Covin RB, Rich NL, Aysola A. Upper‐extrmeity deep venous thrombosis complicating whole‐blood donation. Transfusion 2004; 44:586–590.

76 76. Newman B, Rajpurkar M, Ozgonenel B, et al. Upper‐extremity deep venous thrombosis after whole blood donation: report of three cases from a single blood center. Transfusion 2015; 55(6):1290–1293.

77 77. Lasky LC, Lin A, Kahn RA, McCullough J. Donor platelet response and product quality assurance in plateletpheresis. Transfusion 1981; 21:247.

78 78. Glowitz RJ, Slichter SJ. Frequent multiunit plateletpheresis from single donors: effects on donors’ blood and the platelet yield. Transfusion 1980; 20:199–205.

79 79. Heyns AP, Badenhorst PN, Lotter MG, et al. Kinetics and mobilization from the spleen of indium‐111‐labeled platelets during platelet apheresis. Transfusion 1985; 25:215–218.

80 80. Page EA, Coppock JE, Harrison JF. Study of iron stores in regular plateletpheresis donors. Transfus Med 2010; 20(1):22–29.

81 81. Yuan S, Ziman A, Smeltzer B, et al. Moderate and severe adverse events associated with apheresis donations: incidences and risk factors. Transfusion 2010; 50:478–486.

82 82. Winters JL. Complication of donor apheresis. J Clin Apher 2006; 21:132–141.

83 83. Strauss RG. Mechanism of adverse effects during hemapheresis. J Clin Apher 1996; 11:160–164.

84 84. Olson PR, Cox C, McCullough J. Laboratory and clinical effects on the infusion of ACD solution during plateletpheresis. Vox Sang 1977; 33:79–87.

85 85. Bolan CD, Greer SE, Cecco SA, et al. Comprehensive analysis of citrate effects during plateletpheresis in normal donors. Transfusion 2001; 41:1165–1171.

86 86. Bolan CD, Wesley RA, Yau YY, et al. Randomized placebo‐controlled study of oral calcium carbonate administration in plateletpheresis: I. Associations with donor symptoms. Transfusion 2003; 42:1403–1413.

87 87. Ladenson JH, Miller WV, Sherman LA. Relationship of physical symptoms, ECG, free calcium, and other blood chemistries in reinfusion with citrated blood. Transfusion 1978; 18:670–679.

88 88. Komatsu F, Shikata M. Abnormal electrocardiographic findings in apheresis donors. Transfusion 1988; 28:371–374.

89 89. Laspina SJ, Browne MA, McSweeney EN, et al. QTc prolongation in apheresis platelet donors. Transfusion 2002; 42:899–903.

90 90. Uhl L, Maillet S, King S, Kruskall MS. Unexpected citrate toxicity and severe hypocalcemia during apheresis. Transfusion 1997; 37:1063–1065.

91 91. Howard JE, Perkins HA. Lysis of donor RBC during plateletpheresis with a blood processor. JAMA 1976; 236:289–290.

92 92. Kaur D, Kandwal M. Alarmed or unalarmed!! Donor red cell lysis during plateletpheresis procedure. Transfus Apher Sci 2018; 57:277–280.

93 93. Chao FC, Tullis JL, Tinch J, et al. Plateletpheresis by discontinuous centrifugation: effect of collecting methods on the in vitro function of platelets. Br J Haematol 1979; 39:177–187.

94 94. Bongiovanni MB, Katz RS, Wurzel HA. Long‐term plateletpheresis of a donor. Transfusion 1980; 20:465–466.

95 95. Lazarus EF, Browning J, Norman J, et al. Sustained decreases in platelet count associated with multiple, regular plateletpheresis donations. Transfusion 2001; 41:756–761.

96 96. Strauss RG. Effects on donors of repeated leukocyte losses during plateletpheresis. J Clin Apheresis 1994; 9:130–134.

97 97. Richa E, Krueger P, Burgstaler EA, et al. The effect of double‐ and triple‐apheresis platelet product donation on apheresis donor platelet and white blood cell counts. Transfusion 2008; 48:1325–1332.

98 98. Senhauser DA, Westphal RG, Bohman JE, Neff JC. Immune system changes in cytapheresis donors. Transfusion 1982; 22:302–304.

99 99. Koepke JA, Parks WM, Goeken JA, et al. The safety of weekly plateletpheresis: effect on the donor’s lymphocyte population. Transfusion 1981; 21:59–63.

100 100. Matsui Y, Martin‐Alosco S, Doenges E, et al. Effects of frequent and sustained plateletapheresis on peripheral blood mononuclear cell populations and lymphocyte functions of normal volunteer donors. Transfusion 1986; 26:446–452.

101 101. Wright DG, Karsh J, Fauci AS, et al. Lymphocyte depletion and immunosuppression with repeated leukapheresis by continuous flow centrifugation. Blood 1981; 58:451–458.

102 102. Gansner JM, Papari M, Goldstein J, et al. Severe CD4+ T‐cell lymphopenia is not observed in frequent plateletpheresis donors collected on the Fenwal Amicus. Transfusion 2019; 59(9):2783–2787.

103 103. Rahmani M, Fortin BM, Berliner N, et al. CD4+ T‐cell lymphopenia in frequent platelet donors who have ceased platelet donation for at least 1 year. Transfusion 2019; 59(5):1644–1647.

104 104. Gansner JM, Rahmani M, Jonsson AH, et al. Plateletpheresis‐associated lymphopenia in frequent platelet donors. Blood 2019; 133(6):605–614.

105 105. Zhao J, Gabriel E, Norda R, et al. Frequent platelet donation is associated with lymphopenia and risk of infections: A nationwide cohort study Transfusion DOI: 10.1111/trf.16175